Email updates

Keep up to date with the latest news and content from BMC Veterinary Research and BioMed Central.

Open Access Highly Accessed Research article

Efficacy of clarithromycin on biofilm formation of methicillin-resistant Staphylococcus pseudintermedius

Matthew DiCicco1, Suresh Neethirajan1*, Ameet Singh2 and J Scott Weese3

Author Affiliations

1 School of Engineering, University of Guelph, Ontario, Canada

2 Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Ontario, Canada

3 Department of Pathobiology, Ontario Veterinary College, University of Guelph, Ontario, Canada

For all author emails, please log on.

BMC Veterinary Research 2012, 8:225  doi:10.1186/1746-6148-8-225

Published: 21 November 2012



Surgical site infections (SSIs) caused by biofilm-forming methicillin-resistant Staphylococcus pseudintermedius (MRSP) have emerged as the most common hospital-acquired infections in companion animals. No methods currently exist for the therapeutic remediation of SSIs caused by MRSP in biofilms. Clarithromycin (CLA) has been shown to prevent biofilm formation by Staphylococcus aureus. This study aims to assess the in vitro activity of CLA in eradicating MRSP biofilm formation on various materials.


Quantitative assay results (P = 0.5126) suggest that CLA does not eradicate MRSP biofilm formation on polystyrene after 4 – 24 h growth periods. Scanning electron micrographs confirmed that CLA did not eradicate MRSP biofilm formed on orthopaedic implants.


By determining the in vitro characteristics and activities of MRSP isolates alone and against antibiotics, in vitro models of biofilm related infections can be made. In vitro data suggests that CLA does not effectively eradicate S. pseudintermedius biofilms in therapeutic doses.

MRSP; S. pseudintermedius; Methicillin-resistant; Therapeutic; Bacteria; Biofilm; Macrolide, Clarithromycin